All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
After nearly a decade of effort, biopharmaceutical development company Cytogel Pharma LLC recently moved its lead candidate – a chemically stabilized analogue of endomorphin (EM) 1 designed to treat acute and chronic pain – into the clinic.